These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 29246942

  • 1. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD, Lin AP, Jiang D, Wang L, Suhasini AN, Myers J, Qiu Z, Wölfler A, Sill H, Aguiar RCT.
    Clin Cancer Res; 2018 Mar 01; 24(5):1103-1113. PubMed ID: 29246942
    [Abstract] [Full Text] [Related]

  • 2. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ, Pettitt AR, Slupsky JR.
    J Immunol; 2015 Mar 01; 194(5):2439-46. PubMed ID: 25632006
    [Abstract] [Full Text] [Related]

  • 3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, Chen G, Quéva C, Li L, Tannheimer SL.
    PLoS One; 2017 Mar 01; 12(2):e0171221. PubMed ID: 28178345
    [Abstract] [Full Text] [Related]

  • 4. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, Hsi ED, Hill BT, Almasan A.
    Cell Death Dis; 2019 Dec 04; 10(12):924. PubMed ID: 31801949
    [Abstract] [Full Text] [Related]

  • 5. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V.
    Clin Cancer Res; 2015 Apr 01; 21(7):1537-42. PubMed ID: 25670221
    [Abstract] [Full Text] [Related]

  • 6. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
    Suhasini AN, Wang L, Holder KN, Lin AP, Bhatnagar H, Kim SW, Moritz AW, Aguiar RCT.
    Leukemia; 2016 Mar 01; 30(3):617-626. PubMed ID: 26503641
    [Abstract] [Full Text] [Related]

  • 7. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
    Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.
    Oncotarget; 2014 Feb 28; 5(4):908-15. PubMed ID: 24659719
    [Abstract] [Full Text] [Related]

  • 8. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G, Hassenrück F, Hallek M.
    Drug Des Devel Ther; 2018 Feb 28; 12():2577-2590. PubMed ID: 30174412
    [Abstract] [Full Text] [Related]

  • 9. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T, Robak P.
    Int Rev Immunol; 2013 Aug 28; 32(4):358-76. PubMed ID: 23617253
    [Abstract] [Full Text] [Related]

  • 10. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR.
    Semin Oncol; 2016 Apr 28; 43(2):260-4. PubMed ID: 27040704
    [Abstract] [Full Text] [Related]

  • 11. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM, Cosimo E, Leach MT, Michie AM.
    Br J Haematol; 2011 Apr 28; 153(2):199-211. PubMed ID: 21352196
    [Abstract] [Full Text] [Related]

  • 12. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V, Mraz M.
    Eur J Haematol; 2015 Mar 28; 94(3):193-205. PubMed ID: 25080849
    [Abstract] [Full Text] [Related]

  • 13. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S, Dammeijer F, Hendriks RW.
    Mol Cancer; 2018 Feb 19; 17(1):57. PubMed ID: 29455639
    [Abstract] [Full Text] [Related]

  • 14. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.
    Nature; 2017 Feb 23; 542(7642):489-493. PubMed ID: 28199309
    [Abstract] [Full Text] [Related]

  • 15. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC.
    Future Oncol; 2016 Sep 23; 12(18):2077-94. PubMed ID: 27324214
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.
    Oncotarget; 2015 Dec 29; 6(42):44832-48. PubMed ID: 26540567
    [Abstract] [Full Text] [Related]

  • 17. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA, Okkenhaug K.
    Nat Rev Clin Oncol; 2014 Apr 29; 11(4):184-6. PubMed ID: 24642682
    [Abstract] [Full Text] [Related]

  • 18. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.
    Eur Urol; 2017 Jun 29; 71(6):858-862. PubMed ID: 28108151
    [Abstract] [Full Text] [Related]

  • 19. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V.
    Clin Cancer Res; 2017 Jan 01; 23(1):181-192. PubMed ID: 27342398
    [Abstract] [Full Text] [Related]

  • 20. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A.
    Haematologica; 2015 Dec 01; 100(12):1495-507. PubMed ID: 26628631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.